NCT00151476 2024-09-04
Observational Familial Adenomatous Polyposis Registry Study In Patients Receiving Celecoxib Compared to Control Patients
Pfizer
Terminated
Clinical Trials
11 trialsNCT01545141 2023-10-27
Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer
Roswell Park Cancer Institute
Phase 1/2 Terminated
NCT00503035 2023-02-13
Molecular Targeting of 15-Lipoxygenase-1 (15-LOX-1) for Apoptosis Induction in Human Colorectal Cancers
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01150045 2022-03-22
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery
Alliance for Clinical Trials in Oncology
Phase 3 Unknown
NCT03403634 2022-03-02
Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver
Roswell Park Cancer Institute
Phase 2 Completed
NCT00585312 2021-02-21
CHIP
Pfizer
Phase 3 Terminated
NCT00033371 2020-09-29
Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis
National Cancer Institute (NCI)
Phase 2 Completed
NCT01729923 2018-01-16
ADAPT
University of Washington
Phase 2 Terminated
NCT00582660 2017-06-15
UAB0040
University of Alabama at Birmingham
Phase 2 Completed
NCT00198081 2016-02-29
Use of Celecoxib in Patients With Intraductal Papillary Mucinous Neoplasms (IPMNs)
Indiana University
Phase 2 Terminated
NCT00466505 2012-12-19
Cetuximab & Celecoxib for Metastatic Colorectal Cancer or Colorectal Cancer That Cannot Be Removed by Surgery
Vanderbilt-Ingram Cancer Center
Phase 2 Completed